Studies oncologie
Snel naar
- Studies fase 1 / basket oncologie
- Studies borstkanker
- Studies gynaecologische oncologie
- Studies digestieve oncologie
- Studies hoofd- en halsoncologie
- Studies musculoskeletale oncologie (tumoren van de weke delen)
- Studies hersenkanker
- Studies urologische oncologie
- Studies dermatologische oncologie (huidtumoren)
- Studies thoraxoncologie
University Clinical Research Center Antwerp (UNICCRA)
De research unit is een onderdeel van de oncologische afdeling binnen het UZA. Het doel van de research unit is nieuwe, betere en steeds meer doeltreffendere behandelingen vinden om kankerpatiënten te behandelen. Klinische studies zijn hiervoor de beste methode. Tijdens deze klinische studies kunnen onze onderzoekers bepalen welke behandelingen veiliger, effectiever en beter zijn dan huidige behandelingen. De research unit bestaat uit artsen, studie coördinatoren, logistieke medewerkers, studie verpleegkundigen, pathologen en administratieve medewerkers.
Hoe kan ik de research unit bereiken?
Heb je vragen over de studies binnen de research unit? Neem gerust contact met ons op via 03 821 55 80, 03 821 53 07 of via research [dot] oncologie [at] uza [dot] be.
Studies fase 1/basket oncologie
Title | Tumortype | Line of therapy | Study information | Status | Register |
KISIMA-01: Phase Ib Study to evaluate the safety, tolerability and anti-tumor activity of ATP128, with or without BI 754091 in patients with stage IV CRC |
CRC
|
|
|
Slots | |
MCLA-145-CL01: A Phase 1, Open-label, Dose-escalation study of MCLA-145 in participants with advanced or metastatic malignancies |
|
<=4L |
|
Slots | |
eNRGy: Full molecular testing by RNA/DNA next generation sequencing to detect RNA/DNA alterations (including NRG1 fusions) |
|
All |
|
Open | |
MATTERS: A mono-centric, first in-human (FIH), safety and preliminary efficacy study of (neo)adjuvant, model-based, whole-body hyperthermia (WBHT) treatment in advanced solid cancer patients or stage IV (TxNxM1) metastatic pancreatic adenocarcinoma patients |
Solid - stage IV | All |
|
Open | NCT04467593 |
INCB99280-112: A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors |
|
|
|
Slots | NCT04242199 |
EZH-1201: A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects with Moderate and Severe Hepatic Impairment with Advanced Malignancies. |
All tumortypes with:
|
Prior SOC |
|
Slots |
NCT04241835 |
ARRAY 818-103: An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors |
BRAF V600E/V600K mutated solid tumors |
|
|
On Hold | |
TRIDENT-1: A Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements |
|
|
|
Open | |
JZLA/EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers |
|
|
|
Slots | |
TAPISTRY/BO41932: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study |
|
|
|
Open | |
BI1472-0001: A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation |
|
|
|
Slots | |
MCLA-129: Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors |
|
|
|
Slots | |
OPTIMIZE-1: A phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma |
|
1st line (previously untreated) |
|
Closed | |
GO42144: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation |
KRAS G12C mutated
|
Prior SOC or intolerance |
|
Slots | |
BALLETT: A study to examine the clinical value of comprehensive genomic profiling performed by Belgian NGS laboratories: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre |
All solid tumors | All (early lines are preferred) |
|
Open | |
SGNTUC-019: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations |
|
|
|
Open | |
INCB 99318-122: A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors |
|
|
|
Slots | |
BT5528-100: A Phase I/II study of BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
|
|
|
Slots | |
20210102 (AMG552): A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination with Docetaxel in Subjects with Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201) |
|
|
|
Slots | NCT05267470 |
AMG 20190135: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation |
|
|
|
Slots | NCT04185883 |
CL1-95012-001: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors |
Solid tumors |
|
|
Slots | NCT05159388 |
20210023 (AMG193): AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP) |
|
|
|
Slots | NCT03564340 |
XL092-001: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Soli |
|
|
|
Slots | NCT03845166 |
20210104 (AMG 552): A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) |
|
|
|
Slots | NCT05325866 |
WP43295: A phase 1a/b open-label study to evaluate safety, pharmacokinetics, and preliminary clinical activity of RO7276389 alone and in combination with cobimetinib in participants with BRAF-V600 mutation-positive advanced solid tumor or BRAF-V600 mutation-positive melanoma with central nervous system metastases |
|
Prior SOC |
|
Slots | ISRCTN13713551 |
61186372GIC2002 (ORIGAMI-1): A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer |
CRC with KRAS/NRAS/BRAF/EGFR/HER2 wild type
|
|
|
Slots | NCT05379595 |
TES16382: Open-label study evaluating the effect of tusamitamab ravtansine on the QTc interval in participants with metastatic solid tumors |
|
Prior SOC or intolerant |
|
Slots | NCT05429762 |
20200469: A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer |
|
1L |
|
Slots | NCT05361395 |
MK6482-016: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors |
|
|
|
Slots | NCT04976634 |
KBA1412-101: A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumors |
|
|
|
Slots | NCT05501821 |
DAY101-102: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations |
All solid tumors with:
|
Prior SOC or intolerant |
|
Slots | NCT04985604 |
DO2.22.01: A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours |
All solid tumors with:
|
|
|
Slots | |
INCA0186-101: A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors |
|
Prior SOC |
|
Slots | NCT04989387 |
1403-0011 (Brightline-2): A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours |
MDM2 amplified, TP53 wild-type solid tumours:
|
>1L |
|
Open | NCT05512377 |
1412-0003: A phase Ia/Ib, open label, multicentre, dose escalation study of BI 905711 in combination with chemotherapy followed by expansion cohorts in patients with advanced gastrointestinal cancers |
|
2L |
|
On hold |
Studies borstkanker
Title | Tumortype | Line of therapy | Study information | Status | Register |
The AURORA PROGRAM: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer | All | 1-2L |
|
Hold | NCT02102165 |
SERENA-4: A Randomised, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib vs Anastrozole plus Palbociclib for the Treatment of Patients with ER-Positive, HER2-Negative Advanced Breast Cancer who Have Not Received Any Systemic Treatment for Advanced Disease | HER2-/ER+ | 1L |
|
Open | |
WO41554/INAVO120: Phase III, double-blind, placebo-controlled study evaluating the efficacy and safety of GDC-0077/Placebo plus Palbociclib and Fulvestrant in patients with PIK3CA-mutant, Hormone Receptor-Positive, Her2-Negative locally advanced or metastatic breast cancer. | HER2-/HR+ | 1L |
|
Open | NCT04191499 |
DESTINY-Breast09: Phase III, Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab vs Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast cancer. | HER2+ | 1L |
|
Open | NCT04784715 |
DESTINY-Breast08: Phase Ib of Trastuzumab Deruxtecan (T-DXd) in combination with other Anti-Cancer Agents in patients with Metastatic HER2-low Breast Cancer. | TNBC |
Module 1: 0-2L --> on Hold Module 2: 1L Module 3: 0-2L |
|
Closed | NCT04556773 |
DESTINY-05: A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) vs T-DM1 in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy. |
HER2+ | Adjuvant |
|
Open | NCT04622319 |
lidERA: a phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor positive, her2-negative early breast cancer |
ER+/HER2- | Adjuvant |
|
Open | NCT04961996 |
AL-2001 (Allarity): Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) |
TNBC and HER2-/HR+ | 4L |
|
Open | NCT04796324 |
Studies gynaecologische oncologie
Title | Tumortype | Line of therapy | Study information | Status | Register |
R4018-ONC-1721: Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer |
Ovarian carcinoma of epithelial origin |
|
|
Slots | NCT03564340 |
FLORA-5: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery |
|
|
|
Open | NCT04498117 |
Studies digestieve oncologie
Title | Tumortype | Line of therapy | Study information | Status | Register |
ASPIRIN: A Randomised, double–blind, placebo-controlled Trial of Aspirin to prevent Recurrence | Colon Cancer | Adjuvant |
|
Open | NCT03464305 |
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy YO42137 - SKYSCRAPER-07 |
Unresectable locally advanced esophageal squamous cell carcinoma | 1 |
|
Open | NCT04543617 |
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Intermediate-risk, Stage II-III Rectal Cancer REGINA |
Rectal cancer | Neo-adjuvant |
|
Open | |
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer AT148006 ASPEN-06 |
Advanced gastric or gastroesophageal junction | 2L-3L |
|
Open | |
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression AMGEN 20210096 FORTITUDE-101 |
Advanced gastric or gastroesophageal junction | 1L |
|
Open | |
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen DS8201-A-U306 DESTINY-gastric-04 |
Advanced gastric or gastroesophageal junction | 2L |
|
Open | |
A Trial to Assess Efficacy and Safety of Octreotide (CAM2029) Subcutaneous Depot in Patients With GEP-NET HS-19-657 SORENTO
|
GEP-NET | 2L |
|
Open | |
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation MRTX849 KRYSTAL-10 |
Advanced colorectal cancer | 2L |
|
Open | |
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer AMGEN 20210098 - FORTITUDE-102 |
Unresectable (locally advanced or metastatic) gastric of GEJ adenocarcinoma | 1st line |
|
Open | |
FOLICOLOR Trial: Following therapy response through Liquid Biopsy in metastatic colorectal cancer patients |
(unresectable) Metastatic colorectal Cancer | 1L (2-3L if recurrence) |
|
Open | |
NALPAC: A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + Naliri and 5-FU + Nalirinox for metastatic pandreatic ductal adenocarcinoma |
Metastatic PDAC | 2L |
|
Open | NCT05472259 |
COLIPAN: Collection of Liquid Biopsies in Pancancer patients |
Colon adenomCa, Rectum adenoCa, Pancreas adenoCa, Hepatocellulair Ca, slokdarm plaveivelcelCa | 1L |
|
Open |
Studies hoofd- en halsoncologie
Title | Tumortype | Line of therapy | Study information | Status | Register |
UPSTREAM: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck |
SCCHN:
|
>1L, platinum failed |
|
Open | NCT03088059 |
JZJB/LIBRETTO-531: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer |
Thyroid |
1L |
|
On hold | NCT04211337 |
TACTI-003 (Two ACTive Immunotherapeutics): A multicenter, open label, randomized, Phase II trial to investigate a soluble LAG-3 fusion protein, eftilagimod alpha (efti; IMP321) in combination with pembrolizumab (PD-1 antagonist) for first line treatment of subjects with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) |
Recurrent or metastatic squamous cell carcinoma of the H&N |
1L |
|
Open | NCT04811027 |
ProcemISA: A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16- positive Oropharyngeal Cancer who have experienced disease progression with prior anti-PD-1 therapy |
SCCHN Oropharynx HPV16+ |
2-3L |
|
Open | NCT04398524 |
ELEVATE: A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma |
SCCHN:
|
1L / 2-3L |
|
Open | NCT04854499 |
COLIPAN: collection of Liquid Biopsies in Pancancer patients |
H&N plaveiselcelCa |
1L |
|
Open |
Studies musculoskeletale oncologie (tumoren van de weke delen)
Title | Tumor Type | Line of therapy | Study information | Status | Register |
Studies hersenkanker
Title | Tumor Type | Line of therapy | Study information | Status | Register |
ADDIT-GLIO: Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma | Glioblastoma | Adjuvant |
|
Open | NCT02649582 |
Studies urologische oncologie
Title | Tumor Type | Line of therapy | Study information | Status | Register |
PEACE III: A Randomized phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. | Prostate cancer | >= 1L |
|
open | NCT02194842 |
KEYNOTE-676: A Phase 3, Randomized, Comparator-controlled Clinical Trials to study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction. | Non-muscle invasive bladder carcinoma | Persistent or recurrent following BCG induction |
|
Open | NCT03711032 |
COLIPAN: collection of Liquid Biopsies in Pancancer patients | Prostaat adenoCa | 1L |
|
Open |
Studies dermatologische oncologie (huidtumoren)
Title | Tumor Type | Line of therapy | Study information | Status | Register |
IFX-1-P2.8: Open label, multicenter Phase II study of the C5a-antibody IFX-1 alone or IFX-1 + pembrolizumab in patients with PD-1- or PD-L1-resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) | Cutaneous squamous cell carcinoma |
|
|
Open | NCT04812535 |
Thoraxoncologie
De dienst thoraxoncologie is een onderdeel van het MOCA (Multidisciplinair Oncologisch Centrum Antwerpen) binnen het UZA. We behandelen patiënten met longkanker, longvlieskanker en thymustumoren. Naast standaard behandelingen bieden we ook behandelingen in studieverband aan. Het gaat hier om fase II en III klinische studies. Het doel van een klinische studie is om te onderzoeken of een nieuwe behandeling veiliger, effectiever en beter is dan huidige behandeling. Voor fase I klinische studies verwijzen we u naar de research unit.
Hoe kan ik de dienst thoraxoncologie bereiken?
Heb je vragen over de studies binnen de dienst thoraxoncologie? Neem gerust contact met ons op via 03 821 31 07 of via thoraxoncologie [at] uza [dot] be.
Studies thoraxoncologie
Title | Tumor Type | Line of therapy | Study information | Status | Register |
MARIPOSA-2: A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NSCLC After Osimertinib Failure | NSCLC | 2L-3L |
|
On hold | NCT04988295 |
AcceleRET: A Randomized, Open-Label, Phase 3 Study of Pralsetinib vs SOC for First Line Treatment of RET fusion-positive, Metastatic NSCLC | NSCLC stage III-IV | 1L |
|
Open | NCT04222972 |
CARMEN-LC03: Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic nonsquamous NSCLC patients with CEACAM5 positive tumors | NSCLC | >1L |
|
Open | NCT04154956 |
LUMINOSITY: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ NSCLC |
NSCLC |
2L
|
|
Open | |
ALKALINE: Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor |
NSCLC |
>1L
|
|
Open | |
CARMEN-LC06: Open-label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine in non-squamous NSCLC participants with negative or moderate CEACAM5 expression tumors and high circulating CEA |
NSCLC |
>1L
|
|
Open | |
EVOKE-01: Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic NSCLC With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy |
NSCLC |
2L
|
|
Closed | |
DOLBY-LC01: Clinical verification study of epigenetic biomarker panels for the diagnosis of lung cancer (stage IV) |
NSCLC and healty subjects |
prior to 1L
|
|
Open | |
PACIFIC-8: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab in Participants with Locally Advanced (Stage III), Unresectable NSCLC Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy |
NSCLC stage III, T1c-T3N0M0 |
1L maintenance
|
|
Open | NCT05211895 |
JZJX: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) |
NSCLC IB-IIIA |
1L
|
|
Open | NCT04819100 |
KRYSTAL-7: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced NSCLC with KRAS G12C Mutation |
NSCLC |
1L
|
|
Open | NCT04613596 |
PACIFIC-4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative NSCLC |
NSCLC |
1L
|
|
Open | NCT03833154 |
HiPeRMESO |
Malignant Pleural Mesothelioma |
1L, after induction chemotherapy and surgery
|
|
Open | |
PRIMALung: PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients |
SCLC, any stage |
after 1L
|
|
Open | NCT04790253 |
COLIPAN: collection of liquid biopsies in pancancer patients |
NSCLC adenoCa, NSCLC plaveiselcelCa |
1L
|
|
Open | |
KRYSTAL-12: A Randomized Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients with Previously Treated NSCLC with KRAS G12C Mutation |
NSCLC |
2L
|
|
Open | NCT04685135 |